Patients with primary refractory or relapsed T-cell lymphoma typically have a poor prognosis and limited options for effective targeted therapy. This contrasts with the clinical success of using CD19-specific chimeric antigen receptors (CARs) in immunotherapies for B-cell malignancies. Thus, to begin to achieve the long- term goal of devising a CAR-T cell platform that can be safely and effectively applied in patients with T-cell lymphoma, new Project 2 has selected CD5 as a novel target antigen for CAR-transduced cells. This common surface marker of normal T cells is also expressed by an estimated 85% of T-cell malignancies and functions as a transmembrane inhibitory receptor that attenuates signaling from the antigen receptor of T cells and a subset of B cells. Importantly, CD5-specific CAR-T cell fratricide (self-killing) is limited in our experimental model, allowing the CAR-modified cells to expand normally, after which they display potent and selective cytotoxicity against malignant T cells. Nonetheless, we reasoned that a second target antigen might be helpful, as antigen loss during treatment is a major obstacle to truly successful therapy, in patients receiving CD19-specific CAR-T cells, for example. CD7 was judged the best candidate as it is expressed at a high level on >90% of T-lymphoblastic lymphomas and >60% of mature lymphomas including those lacking CD5. Although in preliminary studies CD7-specific CARs showed strong activity against CD7+ target cells, the transduced T cells did not rapidly downregulate CD7, leading to enhanced fratricide that abrogated further expansion. This pitfall was eliminated by targeted depletion of the antigen in the CAR-modified T cells, a step that did not compromise either expansion or antitumor activity. Given these positive findings, we hypothesize that CD5-specific CAR-T cells can be safely used to target CD5+ T-cell lymphomas and induce complete remissions, and that CD7- cells will continue to expand and function in even in the presence of CD7-directed CARs by T cells. We propose to test each strategy in the following specific aims.
Aim 1 : Manufacture the GMP-grade vector and develop the SOPs needed for a clinical trial of CD5-specific CAR-T cells in T-cell lymphoma, and obtain all necessary local and federal regulatory approval.
Aim 2 : Conduct and evaluate a clinical trial using CD5 CAR-T cells to induce remissions in individuals with residual T-cell lymphoma who would then become eligible for allogeneic stem cell transplant.
Aim 3 : Express the CD7-specific CAR on CD7- effector T cells as a means to increase the range of targetable tumors and overcome CD5 antigen escape. Our proposed studies of CD5-specific CARs and the preclinical development of a CD7-specific CAR will do much to substantiate and advance our CAR-based platform for the treatment of T-cell malignancies and would provide a scientific basis for further optimization.

Public Health Relevance

The success that has marked the use of immune-based therapies for B-cell malignancies has not yet extended to lymphomas of T-cell origin. The research proposed here seeks to narrow that gap by developing and testing novel strategies to eliminate malignant T cells that express the CD5 or CD7 target antigen, or both.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Velasquez, Mireya Paulina; Szoor, Arpad; Vaidya, Abishek et al. (2017) CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Cancer Immunol Res 5:860-870
Gomes-Silva, Diogo; Srinivasan, Madhuwanti; Sharma, Sandhya et al. (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130:285-296
Rouce, Rayne H; Sharma, Sandhya; Huynh, Mai et al. (2017) Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol 176:688-704
Huang, Yung-Hsin; Su, Jianzhong; Lei, Yong et al. (2017) DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biol 18:176
Schmueck-Henneresse, Michael; Omer, Bilal; Shum, Thomas et al. (2017) Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol 199:348-362
Lei, Yong; Zhang, Xiaotian; Su, Jianzhong et al. (2017) Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nat Commun 8:16026
Lulla, Premal; Ramos, Carlos A (2017) Expanding Accessibility to CD19-CAR T Cells: Commercializing a ""Boutique"" Therapy. Mol Ther 25:8-9
Peckham-Gregory, Erin C; Chakraborty, Rikhia; Scheurer, Michael E et al. (2017) A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood 130:2229-2232
Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2017) Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep 21:17-26
Liu, Hao; Shen, Yu; Ning, Jing et al. (2017) Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26:280-291

Showing the most recent 10 out of 244 publications